Bio-Rad Announces CE IVD Marking of Its QX200 Droplet Digital PCR System

The First Digital PCR Instrument With the CE IVD Mark...

Bio-Rad
Feb 25, 2016

HERCULES, CA--(Marketwired - February 25, 2016) - Bio-Rad Laboratories, Inc. (NYSE: BIO) and (NYSE: BIO.B) today announced CE IVD marking for its QX200™ Droplet Digital™ PCR (ddPCR™) System, the first digital PCR system with the CE IVD mark for use as an in vitro diagnostic (IVD) in the European Union.

With the CE IVD mark, medical practitioners in Europe can use the QX200 system for highly-accurate detection and quantification of nucleic acids, aiding clinical decision-making in the treatment of diseases ranging from cancer to transplant rejection and viral infection.

"CE IVD marking of the QX200 ddPCR System is Bio-Rad's first step in extending ddPCR technology to the clinic," said Annette Tumolo, Executive Vice President for Bio-Rad's Digital Biology Group. "As a diagnostic tool, our system is fast and cost-effective, making it ideal for realizing the promise of precision medicine."

One aspect of cancer precision medicine that will be rapidly influenced...

Since 2011, Droplet Digital PCR has been available for research use only. The technology, which partitions a DNA or RNA sample into 20,000 droplets and amplifies targeted sequences within each droplet, allows scientists to precisely detect and quantify low concentrations of target DNA and RNA sequences. This enables a range of important genomic applications, including cancer mutation detection, gene copy number determination, viral load monitoring, and gene edit detection.

About Bio-Rad

Bio-Rad Laboratories, Inc. (NYSE: BIO) and (NYSE: BIO.B) develops, manufactures, and markets a broad range of innovative products and solutions for the life science research and clinical diagnostic markets. The company is renowned for its commitment to quality and customer service among university and research institutions, hospitals, public health and commercial laboratories, as well as the biotechnology, pharmaceutical, and food safety industries. Founded in 1952, Bio-Rad is based in Hercules, California, and serves more than 100,000 research and healthcare industry customers through its global network of operations. The company employs more than 7,700 people worldwide and had revenues exceeding $2 billion in 2015. For more information, please visit www.bio-rad.com.

Interested in reading more?

The Scientist ARCHIVES

Become a Member of

Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member?